SPRY
ARS Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.62
−0.88%Margins
Gross margin
73.9%
EBITDA margin
-177.0%
EBIT margin
-185.0%
Net margin
-184.2%
FCF margin
-168.1%
-1721.8%
Return on equity
-86.3%
Return on assets
-117.5%
Return on invested capital
0.44x
Asset turnover
-$196.4M
Cash from operations
$1.45
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026